Grey Wolf Therapeutics
Novel antigen modulation technology that controls T cells to guide the immune system
$50M Series B+ ·
Led by Intermediate Capital Group · Source: fundraisingfox.com
Total raised: $99M across 2 sourced rounds
All 3 rounds ↓Signals
Grey Wolf Therapeutics | 523 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $50M | fundraisingfox.com | ||
| Series B+ | $49M | fundraisingfox.com | ||
| Series A | undisclosed | globenewswire.com |
Timeline
- X account created
- Website created
Founders and team
TM
Tom McCarthy Non-Executive Director & Co-foundersource: greywolftherapeutics.comPJ
Peter Joyce Chief Executive Officer & Co-founderLinkedIn · source: greywolftherapeutics.comTH
Thierry Hercend Industry Expert Director
Investors
AAndera Partnerslead investor
BBritish Patient Capital
CCanaan Partnerslead investor
EEarlybird VClead investor
IIntermediate Capital Grouplead investor
OOxford Science Enterprises
PPfizer Venture Investmentslead investor
Companies like Grey Wolf Therapeutics
TTinkeso TherapeuticsAAtavistik Bio$40M Series B+ · Mar 2026
NNormunity$75M Series B+ · Jan 2025
QQuanta TherapeuticsSeries B+ · Oct 2026
DDeepflareSeed · Jul 2022
OOblenio Bio$62M Series B+ · Jun 2026
Other companies backed by Intermediate Capital Group
DDraig Therapeutics$65M Series B+ · Jul 2026
MMediar Therapeutics$76M Series B+ · Jan 2026
FF2G$100M Series B+ · Sep 2024
AAmolyt Pharma$140M Series B+ · Jan 2023
Intermediate Capital Group portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/grey-wolf-therapeutics (get a free API key).